SCHEMBL4428966

SCHEMBL4428966

COc1ccc(Cl)cc1S(=O)(=O)N1c2ccccc2NC(=O)[C@H]1CC(=O)NCCc1ccncc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 12/20 0.56
TDP1 Q9NUW8 1/20 0.49
ATM Q13315 1/20 0.48
ALDH1A1 P00352 5/20 0.45
TSHR P16473 1/20 0.45
KDM4E B2RXH2 2/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 2/20 0.45
MEN1 O00255 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.45
POLB P06746 2/20 0.43
MAPK1 P28482 1/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4427038 0.92 BDKRB1 (0.53) BDKRB1ALDH1A1KDM4EMAPTHPGD
SCHEMBL4418562 0.92 BDKRB1 (0.53) BDKRB1ALDH1A1KDM4EMAPTHPGD
SCHEMBL4419774 0.91 BDKRB1 (0.52) BDKRB1TDP1ALDH1A1KDM4EMAPT
SCHEMBL4432022 0.90 BDKRB1 (0.63) BDKRB1ALDH1A1POLB
SCHEMBL4420732 0.87 BDKRB1 (0.53) BDKRB1ALDH1A1KDM4EMAPTHPGD
SCHEMBL4417637 0.85 BDKRB1 (0.65) BDKRB1ALDH1A1POLB
SCHEMBL4429685 0.85 BDKRB1 (0.62) BDKRB1ALDH1A1KDM4EPOLB
SCHEMBL4422605 0.84 BDKRB1 (0.59) BDKRB1ALDH1A1POLB
SCHEMBL4421238 0.84 BDKRB1 (0.59) BDKRB1ALDH1A1POLB
SCHEMBL4431283 0.84 BDKRB1 (0.59) BDKRB1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7056937-B2 Sulfonylquinoxalone derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2006-06-06 US claimed
US-20040147519-A1 Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-29 US claimed
US-7635775-B2 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2009-12-22 US disclosed
US-7183281-B2 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2007-02-27 US disclosed
US-20060293332-A1 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2006-12-28 US disclosed
US-7056937-B2 Sulfonylquinoxalone derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2006-06-06 US disclosed
US-20040147519-A1 Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-29 US disclosed
US-20040147520-A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293332-A1 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists BDKRB2, BDKRB1, PDXK BDKRB1 2/4885TDP1 4459/4885ATM 2064/4885
US-20040147519-A1 Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists BDKRB2, BDKRB1, HRH2 BDKRB1 2/4885TDP1 4539/4885ATM 2402/4885
US-20040147520-A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists BDKRB2, BDKRB1, PDXK BDKRB1 2/4885TDP1 4513/4885ATM 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.